Production (Stage)
Bicycle Therapeutics plc
BCYC
$8.05
-$0.05-0.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.72M | 35.28M | 36.90M | 39.57M | 41.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.72M | 35.28M | 36.90M | 39.57M | 41.61M |
| Cost of Revenue | 80.40M | 56.07M | 168.05M | 160.58M | 159.42M |
| Gross Profit | -50.97M | -17.09M | -131.15M | -121.00M | -117.81M |
| SG&A Expenses | 76.79M | 72.18M | 65.29M | 62.39M | 62.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 274.08M | 245.15M | 233.34M | 222.97M | 221.47M |
| Operating Income | -248.36M | -209.87M | -196.44M | -183.40M | -179.86M |
| Income Before Tax | -208.72M | -173.80M | -169.64M | -163.02M | -166.44M |
| Income Tax Expenses | -5.50M | -4.77M | -3.36M | 2.36M | 1.73M |
| Earnings from Continuing Operations | -203.22 | -169.03 | -166.28 | -165.37 | -168.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -203.22M | -169.03M | -166.28M | -165.37M | -168.16M |
| EBIT | -248.36M | -209.87M | -196.44M | -183.40M | -179.86M |
| EBITDA | -241.21M | -202.70M | -189.32M | -176.75M | -173.21M |
| EPS Basic | -3.13 | -2.88 | -3.28 | -3.81 | -4.45 |
| Normalized Basic EPS | -2.04 | -1.87 | -2.07 | -2.34 | -2.76 |
| EPS Diluted | -3.13 | -2.88 | -3.28 | -3.81 | -4.45 |
| Normalized Diluted EPS | -2.04 | -1.87 | -2.07 | -2.34 | -2.76 |
| Average Basic Shares Outstanding | 259.23M | 232.59M | 205.96M | 176.55M | 154.75M |
| Average Diluted Shares Outstanding | 259.23M | 232.59M | 205.96M | 176.55M | 154.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |